Kura Oncology Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Total Funding:$205M
Industry:Biotech
Founded:2014
Lead Investor(s):Leerink Partners, Cowen

Industry Ranking

Estimated Revenue & Financials

  • Kura Oncology's estimated annual revenue is currently $5.7M per year.
  • Kura Oncology received $Undisclosed in venture funding in August 2017.
  • Kura Oncology's estimated revenue per employee is $119,479
  • Kura Oncology's total funding is $205M.

Employee Data

  • Kura Oncology has 48 Employees.
  • Kura Oncology grew their employee count by 14% last year.
  • Kura Oncology currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
#1
$7M4510%N/A-N/A
#2
N/A205N/AN/A-N/A
#3
$46.8M3024%N/A-N/A
#4
$22.3M144N/AN/A-N/A
#5
$44.3M286N/AN/A-N/A
#6
$101.2M65346%N/A-N/A
#7
$33.3M2153%N/A-N/A
#8
$28.7M1858%N/A-N/A
#9
$39.4M254N/AN/A-N/A
#10
$6.5M4214%N/A-N/A
Missing a competitor? Contribute!?
Submit

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Our lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials in solid tumor and hematologic indications. Our pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 dose-escalation trial, and KO-539, a menin-MLL inhibitor, currently in preclinical development. For additional information, please visit our website at www.kuraoncology.com.

keywords:Biotechnology,Healthcare,Pharmaceuticals

48

Number of Employees

$5.7M

Revenue (est)

1

Current Jobs

14%

Employee Growth %

$205M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Kura Oncology News

09/09/2019 - Analyzing Kura Oncology, Inc. (KURA) From Top to Bottom,

On Thursday, shares of Kura Oncology, Inc. (NASDAQ:KURA) marked $16.14 per share versus a previous $15.24 closing price. With having a ...

08/12/2019 - Kura Oncology Announces Appointment of Kathleen Ford as ...

SAN DIEGO, Aug. 12, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused ...

09/03/2019 - Kura Oncology Announces Positive Phase 2 Trial of Tipifarnib ...

03, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the ...

Kura Oncology Funding

DateAmountRoundLead InvestorsReference
2015-03-16$60.0MUndisclosedArticle
2015-10-30$60.0MUndisclosedCitigroupArticle
2017-08-11$UndisclosedUndisclosedLeerink PartnersArticle

Kura Oncology Executive Hires

DateNameTitleReference
2018-06-21John FarnamChief Operating OfficerArticle
2018-08-01Marc GrassoCFO & Chief Business OfficeArticle